Provectus Biopharmaceuticals verlängert automatisches Umwandlungsdatum für Vorzugsaktien bis 2028
I'm PortAI, I can summarize articles.
Provectus Biopharmaceuticals Inc. has announced the extension of the automatic conversion date for its Series D and Series D-1 Convertible Preferred Stock into common stock from June 20, 2026, to December 31, 2028. The changes were approved by the board and a special committee consisting solely of independent members.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments